Trimipramine maleate - Generic Drug Details

What are the generic sources for trimipramine maleate and what is the scope of patent protection?

Trimipramine maleate is the generic ingredient in two branded drugs marketed by Teva Womens, Breckenridge, Elite Labs Inc, and Usl Pharma, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for trimipramine maleate. Three suppliers are listed for this compound.

Summary for trimipramine maleate

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	6
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	67
Patent Applications:	1,086
Drug Prices:	Drug price trends for trimipramine maleate
What excipients (inactive ingredients) are in trimipramine maleate?	trimipramine maleate excipients list
DailyMed Link:	trimipramine maleate at DailyMed

See drug prices for trimipramine maleate

Pharmacology for trimipramine maleate

Drug Class

Tricyclic Antidepressant

Medical Subject Heading (MeSH) Categories for trimipramine maleate

Adrenergic Uptake Inhibitors

Antidepressive Agents, Tricyclic

Anatomical Therapeutic Chemical (ATC) Classes for trimipramine maleate

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for trimipramine maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Elite Labs Inc	TRIMIPRAMINE MALEATE	trimipramine maleate	CAPSULE;ORAL	077361-002	Aug 2, 2006	AB	RX	No	No
Teva Womens	SURMONTIL	trimipramine maleate	CAPSULE;ORAL	016792-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Elite Labs Inc	TRIMIPRAMINE MALEATE	trimipramine maleate	CAPSULE;ORAL	077361-003	Aug 2, 2006	AB	RX	No	No
Usl Pharma	TRIMIPRAMINE MALEATE	trimipramine maleate	CAPSULE;ORAL	071283-001	Dec 8, 1987		DISCN	No	No
Breckenridge	TRIMIPRAMINE MALEATE	trimipramine maleate	CAPSULE;ORAL	208127-001	Apr 15, 2016	AB	RX	No	No

Trimipramine maleate Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Trimipramine Maleate?

Trimipramine maleate is a tricyclic antidepressant primarily prescribed for depression, anxiety, and sleep disorders. Although once widely used, its market presence has diminished due to advances in newer antidepressants with better safety profiles.

Market Size and Share

• The global antidepressant market was valued at approximately $16.4 billion in 2022 [1]. Trimipramine maleate accounted for less than 1% of this, with sales estimates around $150 million annually.
• Usage peaks in regions with less access to newer therapies, including parts of Asia and Eastern Europe.

Competitive Landscape

• Dominated by selective serotonin reuptake inhibitors (SSRIs) like fluoxetine and sertraline, which have fewer side effects.
• Trimipramine's decline relates to its side effect profile, notably anticholinergic effects and sedation.

Regulatory Environment

• Limited recent approvals for new formulations or indications.
• In some countries, regulatory agencies have withdrawn or restricted prescriptions due to safety concerns.

Prescriber Trends

• Preference shifts towards medications with improved safety, fewer interactions, and better tolerability.
• Off-label use for sleep disorders persists but is less prominent.

Side Effect Issues and Market Constraints

• Significant anticholinergic effects: dry mouth, urinary retention, cardiovascular risks.
• Long-term safety data is less comprehensive than for newer agents.

How Has the Financial Trajectory Evolved?

Historical Sales Data

Year	Global Sales (USD millions)	Notes
2010	200	Peak period with wider prescribing practices
2015	180	Slight decline, growing preference for SSRIs
2020	150	Further decline, safety concerns intensify
2022	Approx. 150	Stabilized, minimal growth

Revenue Trends

• The decline is driven by patent expiries in some markets (though trimipramine is off-patent).
• Pharmaceutical companies have reduced marketing efforts.
• Off-label use sustains minimal revenue streams.

Future Outlook

• Expect continued decline due to generics saturation and preference for newer drugs.
• Small niche markets may persist in specific regions or indications, such as sleep disorders in patients intolerant to other medications.

What Is the R&D and Investment Outlook?

• Limited pipeline development exists for trimipramine maleate.
• R&D efforts focus on novel antidepressants targeting different pathways.
• Investment in reformulation or new indications is minimal, reflecting reduced market potential.

Key Factors Influencing Market and Revenue

• Safety profile considerations.
• Healthcare provider preferences trending toward safer, more tolerable options.
• Regulatory restrictions driven by safety concerns.
• Market saturation with generic drugs and declining demand.

Key Takeaways

• Trimipramine maleate's market has shrunk from a peak of approximately $200 million in 2010 to around $150 million in 2022.
• The drug's decline stems from safety issues, side effect profile, and competition from newer antidepressants.
• The outlook suggests further market contraction with negligible new R&D investment.
• Its presence persists mainly in niche markets and regions with limited access to newer agents.
• Regulatory restrictions could impact future availability.

FAQs

1. Why has the market share for trimipramine maleate declined?
Safety concerns, side effect profiles, and the availability of newer antidepressants with better tolerability have reduced its prescription rate.

2. Are there ongoing developments or new formulations for trimipramine maleate?
No significant R&D R processes for new formulations or indications are reported, given its diminished market role.

3. Which regions still use trimipramine maleate?
Limited use occurs in Asia and Eastern Europe, primarily where newer drugs are less accessible or not approved.

4. How does the side effect profile compare with other antidepressants?
It causes anticholinergic effects and sedation more frequently than SSRIs and SNRIs, which are generally better tolerated.

5. What are the future market prospects?
Continued decline is expected, with potential for small niche markets but negligible growth prospects.

---

References

1. Grand View Research, "Antidepressant Market Size, Share & Trends Analysis Report," 2022.